Online First

August 11, 2020

Correspondence
Glucosamine and mortality: a note of caution
Free

Richard Conway

doi: 10.1136/annrheumdis-2020-218489
Correspondence response
Response to: ‘Glucosamine and mortality: a note of caution’ by Conway
Free

Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Xi-Ru Zhang, Chen Mao

doi: 10.1136/annrheumdis-2020-218660

August 07, 2020

Correspondence
No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
Free

Peer Aries, Christof Iking-Konert

doi: 10.1136/annrheumdis-2020-218400
Correspondence
Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al
Free

Chien Hsien Lo, Yu-Hsun Wang, Chin Feng Tsai, Kuei Chuan Chan, Li Ching Li, Tse Hsien Lo, Chun Hung Su, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218589
Correspondence
Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
Free

Ryu Watanabe, Motomu Hashimoto

doi: 10.1136/annrheumdis-2020-217995
Correspondence response
Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef et al’ by Lo et al
Free

Ali Duarte-García, Elizabeth R Graef, Jean W Liew, Maximilian F Konig, Alfred Hyoungju Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-218680

August 05, 2020

Correspondence response
Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al
Free

Kornelis SM van der Geest, Bhaskar Dasgupta

doi: 10.1136/annrheumdis-2020-218654
Correspondence response
Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al
Free

Manuel Francisco Ugarte-Gil, Maximilian F Konig, Peter Korsten, Francis Berenbaum, Alfred Hyoungju Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-218683
Correspondence
COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs
Free

Khalil Ansarin, Ali Taghizadieh, Saeid Safiri, Aida Malek Mahdavi, Shirin Ranjbar, Soheil Teymouri, Masoud Ahangari Maleki, Alireza Khabbazi

doi: 10.1136/annrheumdis-2020-218737
Correspondence
Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care
Free

Juan Molina Collada, Julia Martínez-Barrio, Belén Serrano-Benavente, Isabel Castrejón, Liz Rocío Caballero Motta, Laura Trives Folguera, José María Álvaro-Gracia

doi: 10.1136/annrheumdis-2020-218631
Correspondence response
Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al
Free

Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, Ulrich Meinzer, Albert Faye, Isabelle Melki Great Paris Region (GPR) Kawa-COVID-19 consortium

doi: 10.1136/annrheumdis-2020-218614
Correspondence
Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future
Free

Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst

doi: 10.1136/annrheumdis-2020-218594
Correspondence
Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al
Free

Rosa Pino, Ana Carolina Izurieta, María Ríos-Barnés, Sílvia Ricart, Mariona F De Sevilla, Laura Monfort, Cristian Launes, Iván Cano, Laura Lecina, Judith Sánchez Manubens, Juan Manuel Mosquera, Iolanda Jordan, Joan Sánchez de Toledo, Manuel Monsonís, Cristina Esteva, Carmen Muñoz-Almagro, Victòria Fumadó, Clàudia Fortuny, Juan José Garcia Garcia, Antoni Noguera-Julian, Jordi Anton On behalf of the Kids Corona Project

doi: 10.1136/annrheumdis-2020-218538
Correspondence response
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al
Free

Janine A Lamb, Spyridon Megremis, Hector Chinoy

doi: 10.1136/annrheumdis-2020-218712

August 04, 2020

Correspondence response
Response to: ‘Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al’ by Colunga-Pedraza et al
Free

Kanika Monga, Jean Liew

doi: 10.1136/annrheumdis-2020-218630
Correspondence
Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al
Free

Hann-Ziong Yueh, Chih-Jung Yeh, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218486
Correspondence response
Response to: ‘Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al’ by Yueh et al
Free

Zhi-Hao Li, Wen-Fang Zhong, Qing-Mei Huang, Xi-Ru Zhang, Chen Mao

doi: 10.1136/annrheumdis-2020-218659
Correspondence
Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al
Free

Iris J Colunga-Pedraza, Rosa I Arvizu-Rivera, Griselda Serna-Peña, Ana Laura De-Leon-Ibarra, Deshire Alpizar Rodriguez, Alejandra Pérez-Villar, Mayra Alejandra Reyes Soto, Dionicio Angel Galarza-Delgado

doi: 10.1136/annrheumdis-2020-218541
Correspondence
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al
Free

Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni

doi: 10.1136/annrheumdis-2020-218377
Correspondence
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Free

Maurizio Benucci, Luca Quartuccio, Francesca Li Gobbi, Arianna Damiani, Valentina Grossi, Maria Infantino, Mariangela Manfredi

doi: 10.1136/annrheumdis-2020-218590
Correspondence response
Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al
Free

Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

doi: 10.1136/annrheumdis-2020-218444
Correspondence
Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing
Free

Paola Conigliaro, Silvia Laura Bosello, Cristina Iannuccelli, Elisa Gremese, Francesca Romana Spinelli, Marta Vadacca, Maria Sole Chimenti

doi: 10.1136/annrheumdis-2020-218516
Correspondence
Transient monoarthritis and psoriatic skin lesions following COVID-19
Free

Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti

doi: 10.1136/annrheumdis-2020-218520
Correspondence
Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al

Ran Cui, Qian Wang, Hua Zhang, Shan Wu, Xin-Jian Wan, Sheng-Ming Dai

doi: 10.1136/annrheumdis-2020-218546
Correspondence response
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al
Free

Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko

doi: 10.1136/annrheumdis-2020-218686
Correspondence response
Response to: ‘Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew–gender discrepancies at annual EULAR congresses: towards the gap narrowing’ by Conigliaro et al
Free

Kanika Monga, Jean Liew

doi: 10.1136/annrheumdis-2020-218628
Correspondence response
Gastrointestinal SLE involvement in SLE classification. Response to: ‘‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al’ by Cui et al
Free

Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson

doi: 10.1136/annrheumdis-2020-218615

July 31, 2020

Correspondence response
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Free

Pier Leopoldo Capecchi, Pietro Enea Lazzerini

doi: 10.1136/annrheumdis-2020-218627
Correspondence
Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’
Free

Attila Pethoe-Schramm, Jenny Devenport, William Reiss

doi: 10.1136/annrheumdis-2020-218365
Correspondence response
Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al
Free

Inbal Haya Shafran, Farideh Alasti, Josef S Smolen, Daniel Aletaha

doi: 10.1136/annrheumdis-2020-218403
Correspondence response
Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Free

Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

doi: 10.1136/annrheumdis-2020-218626
Correspondence
Rational use of tocilizumab in COVID-19
Free

Siddharth Jain, Shefali Khanna Sharma

doi: 10.1136/annrheumdis-2020-218519
Correspondence response
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli
Free

Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218612
Correspondence
More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia
Free

Gianfranco Ferraccioli

doi: 10.1136/annrheumdis-2020-218523

July 30, 2020

Correspondence
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al
Free

Ioana Andreica, David Kiefer, Guenther A Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, Xenofon Baraliakos, Juergen Braun

doi: 10.1136/annrheumdis-2020-218609

July 28, 2020

Correspondence
Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?
Free

Akpabio Akpabio, Richard Oluyinka Akintayo, Utibe Effiong

doi: 10.1136/annrheumdis-2020-218449
Correspondence response
Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al
Free

Francesco Caso, Antonio del Puente, Nicolò Girolimetto, Marco Tasso, Corrado Caso, Raffaele Scarpa, Luisa Costa

doi: 10.1136/annrheumdis-2020-218472
Correspondence
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Free

Dennis Scheicht

doi: 10.1136/annrheumdis-2020-217041
Correspondence
External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies
Free

Queenie Luu, Jessica Day, Alix Hall, Vidya Limaye, Gabor Major

doi: 10.1136/annrheumdis-2020-217568

July 24, 2020

Correspondence
Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?

Emine Duran, Levent Kilic, Gamze Durhan, Ahmet Çağkan Inkaya, Gulay Sain Guven, Gul Karakaya, Orhan Macit Ariyurek, Omer Karadag

doi: 10.1136/annrheumdis-2020-218533
Correspondence response
Response to: ‘External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies’ by Luu et al
Free

Masatoshi Jinnin, Akiko Ohta, Hitoshi Kohsaka

doi: 10.1136/annrheumdis-2020-217635
Correspondence
Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia
Free

Sharifah Aishah Wan, Cheng Lay Teh, Benjamin Sachdev Manjit Singh, Yaw Kiet Cheong, Seow Lin Chuah, Ahmad Tirmizi Jobli

doi: 10.1136/annrheumdis-2020-218425
Correspondence
Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’
Free

Xiao-Huan Chen, Chih-Jung Yeh, Han-You Mo, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2020-218451
Correspondence response
Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al
Free

Jixin Zhong, Lingli Dong

doi: 10.1136/annrheumdis-2020-218441
Correspondence response
Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al
Free

Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong

doi: 10.1136/annrheumdis-2020-218508

July 22, 2020

Correspondence
Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study
Free

George N Goulielmos, Maria I Zervou

doi: 10.1136/annrheumdis-2020-218128
Correspondence response
Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al
Free

Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim

doi: 10.1136/annrheumdis-2020-218432
Correspondence
Microbiome in Sjögren’s syndrome: here we are
Free

Taco A van der Meulen, Arjan Vissink, Hendrika Bootsma, Fred K L Spijkervet, Frans G M Kroese

doi: 10.1136/annrheumdis-2020-218213
Correspondence response
Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study’ by Goulielmos and Zervou
Free

Fang Xiao Zhu, Jing-Yang Huang, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218177
Correspondence response
Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al
Free

Julia Manasson, Rebecca B Blank, Jose U Scher

doi: 10.1136/annrheumdis-2020-218327

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

August 11, 2020

August 07, 2020

August 05, 2020

August 04, 2020

July 31, 2020

July 30, 2020

July 28, 2020

July 24, 2020

July 22, 2020

Pages